Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, FORD KATHLEEN, holds the title of Chief Operating Officer at Kura Oncology, Inc..
On 2026-11-16, the insider transacted 10,710 shares.The shares were transacted at a weighted average price of $7.45 per share, resulting in a total market-relevant value of $80K.
FORD KATHLEEN (Chief Operating Officer) sold $80K of $KURA
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.